

## Overview

### Useful For

Distinguishing desmoid-type fibromatosis from other soft tissue tumors by assessing gene targets within the *BCAT (CTNNB1)* gene

This test is **not useful** for hematological malignancies.

### Additional Tests

Test ID	Reporting Name	Available Separately	Always Performed
SLIRV	Slide Review in MG	No, (Bill Only)	Yes

### Testing Algorithm

When this test is ordered, slide review will always be performed at an additional charge.

### Special Instructions

- [Tissue Requirements for Solid Tumor Next-Generation Sequencing](#)

### Method Name

Polymerase Chain Reaction (PCR)-Based Next-Generation Sequencing

### NY State Available

Yes

## Specimen

### Specimen Type

Varies

### Necessary Information

Pathology report (final or preliminary) at minimum containing the following information must accompany specimen in order for testing to be performed:

1. Patient name
2. Block number-must be on all blocks, slides and paperwork (can be handwritten on the paperwork)
3. Tissue collection date
4. Source of the tissue

### Specimen Required

**This assay requires at least 20% tumor nuclei.**

-Preferred amount of tumor area with sufficient percent tumor nuclei: tissue144 mm(2)

---

-Minimum amount of tumor area: tissue 36 mm(2).

-These amounts are cumulative over up to 10 unstained slides and must have adequate percent tumor nuclei.

-Tissue fixation: 10% neutral buffered formalin, not decalcified

-For specimen preparation guidance, see [Tissue Requirement for Solid Tumor Next-Generation Sequencing](#) in Special Instructions. In this document, the sizes are given as 4mm x 4mm x 10 slides as preferred: approximate/equivalent to 144 mm(2) and the minimum as 3mm x 1mm x 10 slides: approximate/equivalent to 36mm(2).

**Preferred:**

**Specimen Type:** Tissue block

**Collection Instructions:** Submit a formalin-fixed, paraffin-embedded tissue block with acceptable amount of tumor tissue.

**Acceptable:**

**Specimen Type:** Tissue slide

**Slides:** 1 stained and 10 unstained

**Collection Instructions:** Submit 1 slide stained with hematoxylin and eosin and 10 unstained, nonbaked slides with 5-micron thick sections of the tumor tissue.

Note: The total amount of required tumor nuclei can be obtained by scraping up to 10 slides from the same block.

**Specimen Type:** Cytology slide (direct smears or ThinPrep)

**Slides:** 1 to 3 slides

**Collection Instructions:** Submit 1 to 3 slides stained and cover slipped with a preferred total of 5000 nucleated cells or a minimum of at least 3000 nucleated cells.

Note: Glass coverslips are preferred; plastic coverslips are acceptable but will result in longer turnaround times.

**Additional Information:** Cytology slides will not be returned.

**Forms**

If not ordering electronically, complete, print, and send an [Oncology Test Request](#) (T729) with the specimen.

**Specimen Minimum Volume**

See Specimen Required

**Reject Due To**

--

Other	Specimens that have been decalcified (all methods) Specimens that have not been formalin-fixed, paraffin-embedded
-------	--

### Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Varies	Ambient (preferred)		
	Frozen		
	Refrigerated		

### Clinical and Interpretive

#### Clinical Information

Desmoid-type fibromatosis is a locally invasive soft tissue tumor. The histological diagnosis of desmoid-type fibromatosis is challenging. Mutations in exon 3 of the beta-catenin (*BCAT* also known as *CTNNB1*) gene have been identified in 50% to 87% of desmoid-type fibromatosis, including T41A (121 A->G), S45P (133 T->C), and S45F (134 C->T), but not in other soft tissue tumors. Patients harboring beta-catenin mutations may have a higher recurrence rate compared to the patients with wild-type beta-catenin.

Next-generation sequencing has recently emerged as an accurate, cost-effective method to identify alterations across numerous genes. This test uses formalin-fixed paraffin-embedded tissue or cytology slides to assess for common somatic mutations in the beta-catenin gene known to be associated with desmoid-type fibromatosis. The results of this test can be useful for supporting a diagnosis of desmoid-type fibromatosis and predicting prognosis.

#### Reference Values

An interpretative report will be provided.

#### Interpretation

An interpretative report will be provided.

#### Cautions

This test cannot differentiate between somatic and germline alterations. Additional testing may be necessary to clarify the significance of results if there is a potential hereditary risk.

DNA variants of uncertain significance may be identified.

A negative (wild-type) result does not rule out the presence of a mutation that may be present but below the limits of detection of this assay.

Point mutations and small insertion/deletion mutations will be detected with in the *BCAT* (*CTNNB1*) gene only. This test does not detect large single or multiexon deletions, or duplications or genomic copy number variants.

Rare polymorphisms may be present that could lead to false-negative or false-positive results. Test results should be interpreted in the context of clinical findings, tumor sampling and other laboratory data. If results obtained do not match other clinical or laboratory findings, contact the laboratory for updated interpretation. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.

Reliable results are dependent on adequate specimen collection and processing. This test has been validated on cytology slides and formalin-fixed, paraffin-embedded tissues; other types of fixatives are discouraged. Improper treatment of tissues, such as decalcification, may cause PCR failure.

### Supportive Data

This next-generation sequencing assay detects somatic mutations that can be used to assist in the diagnosis of desmoid-type fibromatosis and predicting prognosis.

This assay has been shown to be very reproducible, having a 100% concordance for intra- and interassay reproducibility experiments. All somatic mutations that had been previously identified by various other molecular methods were detected by this assay during accuracy studies. No pathogenic variants were detected in known mutation-negative samples.

### Clinical Reference

1. Lazar AJ, Tuvin D, Hajibashi S, et al: Specific mutations in the beta-catenin gene (*CTNNB1*) correlate with local recurrence in sporadic desmoid tumors. *Am J Pathol* 2008;173:1518-1527
2. Amary MF, Pauwels P, Meulemans E, et al: Detection of beta-catenin mutations in paraffin-embedded sporadic desmoid-type fibromatosis by mutation-specific restriction enzyme digestion (MSRED): an ancillary diagnostic tool. *Am J Surg Pathol* 2007;31:1299-1309
3. Domont J, Salas S, Lacroix L, et al: High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management. *Br J Cancer* 2010;102:1032-1036

### Performance

### Method Description

Next-generation sequencing is performed to test for the presence of a mutation in targeted regions of the *BCAT* (*CTNNB1*) gene, including exon 3, codons 25-66.(Unpublished Mayo method).

Gene	GenBank Accession Number	Nucleotide Start	Nucleotide End	Chromosome	Exon	Codons
<i>CTNNB1</i>	NM_001904	41266076	41266199	Chromosome 3	Exon 3	25-66

### PDF Report

No

### Day(s) Performed

Monday through Friday

### Report Available

12 to 20 days

### Specimen Retention Time

Unused portions of blocks will be returned to the client. Unused slides are stored indefinitely.

**Performing Laboratory Location**

Rochester

**Fees and Codes****Fees**

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their Regional Manager. For assistance, contact [Customer Service](#).

**Test Classification**

This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

**CPT Code Information**

81403

88381

**LOINC® Information**

Test ID	Test Order Name	Order LOINC Value
CTNNB	B-Catenin Mutation Analysis, Tumor	21659-8

Result ID	Test Result Name	Result LOINC Value
92365	Result Summary	50397-9
92366	Result	21659-8
92367	Interpretation	69047-9
92368	Additional Information	48767-8
92369	Specimen	31208-2
92370	Source	31208-2
92371	Tissue ID	80398-1
92372	Released By	18771-6